FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2144365452> ?p ?o ?g. }

• W2144365452 endingPage "13432" @default.
• W2144365452 startingPage "13427" @default.
• W2144365452 abstract "Human herpesvirus 8 (HHV8) is the primary viral etiologic agent in Kaposi's sarcoma (KS). However, individuals dually infected with both HHV8 and human immunodeficiency virus type 1 (HIV-1) show an enhanced prevalence of KS when compared with those singularly infected with HHV8. Host immune suppression conferred by HIV infection cannot wholly explain this increased presentation of KS. To better understand how HHV8 and HIV-1 might interact directly in the pathogenesis of KS, we queried for potential regulatory interactions between the two viruses. Here, we report that HHV8 and HIV-1 reciprocally up-regulate the gene expression of each other. We found that the KIE2 immediate-early gene product of HHV8 interacted synergistically with Tat in activating expression from the HIV-1 long terminal repeat. On the other hand, HIV-1 encoded Tat and Vpr proteins increased intracellular HHV8-specific expression. These results provide molecular insights correlating coinfection with HHV8 and HIV-1 with an unusually high incidence of KS. Human herpesvirus 8 (HHV8) is the primary viral etiologic agent in Kaposi's sarcoma (KS). However, individuals dually infected with both HHV8 and human immunodeficiency virus type 1 (HIV-1) show an enhanced prevalence of KS when compared with those singularly infected with HHV8. Host immune suppression conferred by HIV infection cannot wholly explain this increased presentation of KS. To better understand how HHV8 and HIV-1 might interact directly in the pathogenesis of KS, we queried for potential regulatory interactions between the two viruses. Here, we report that HHV8 and HIV-1 reciprocally up-regulate the gene expression of each other. We found that the KIE2 immediate-early gene product of HHV8 interacted synergistically with Tat in activating expression from the HIV-1 long terminal repeat. On the other hand, HIV-1 encoded Tat and Vpr proteins increased intracellular HHV8-specific expression. These results provide molecular insights correlating coinfection with HHV8 and HIV-1 with an unusually high incidence of KS. Human herpesvirus 8 (HHV8),1 or Kaposi's sarcoma-associated herpesvirus, is the first human member of γ2-herpes viruses (1Chang Y. Cesarman E. Pessin M.S. Lee F. Culpepper F. Knowles D.M. Moore P.S. Science. 1994; 266: 1865-1869Crossref PubMed Scopus (4952) Google Scholar, 2Noore P.S. Gao S.J. Dominguez G. Gesarman E. Lungu O. Knowles D.M. Garber R. Pellett P.E. McGeoch E.J. Chang Y. J. Virol. 1996; 70: 549-558Crossref PubMed Google Scholar, 3Russo J.J. Bohenqky R.A. Chien M.-C. Chien J. Yan M. Maddalena E. Parry J.P. Peruzzi D. Edelman E.S. Chang Y. Moore P.S. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 14862-14867Crossref PubMed Scopus (1304) Google Scholar). HHV8 has been identified in Kaposi's sarcoma (KS) (4Moore P.S. Chang Y. N. Engl. J. Med. 1995; 332: 1181-1185Crossref PubMed Scopus (1081) Google Scholar, 5Huang Y.Q. Li J.J. Kaplan M.H. Poiesz B. Katabira E. Zhang W.C. Feiner D. Firedman-Kien A.E. Lancet. 1995; 345: 759-761Abstract PubMed Scopus (387) Google Scholar, 6Cathomas G. McGandy C.E. Teracciano L.M. Itin P.H. DeRosan G. Gudat F. J. Clin. Pathol. 1996; 49: 631-633Crossref PubMed Scopus (44) Google Scholar, 7Noel J.C. Hermans P. Andre J. Fayt I. Simonart Th. Verhest A. Haot J. Burny A. Cancer. 1996; 77: 2132-2136Crossref PubMed Scopus (79) Google Scholar, 8Buonaguro F.M. Tornesello M.L. Beth-Giraldo E. Hatzakis A. Mueller N. Downing R. Biryamwaho B. Sempala D.K. Giraldo G. Int. J. Cancer. 1996; 65: 25-28Crossref PubMed Scopus (118) Google Scholar), primary effusion lymphoma (also termed body cavity-based lymphoma or BCBL) (9Cesarman E. Chang Y. Moore P.S. Said J.W. Knowles D.M. N. Engl. J. Med. 1995; 332: 1186-1191Crossref PubMed Scopus (2492) Google Scholar, 10Nador R.G. Cesarman E. Chadbrun A. Dawson D.B. Ansari M.Q. Said J.W. Knowles D.M. Blood. 1996; 88: 645-656Crossref PubMed Google Scholar), and multicentric Castleman's disease (11Soulier J. Grollet L. Oksenhendler E. Cacoub P. Cazals-Hatem D. Babinet P. d'Agay M.-F. Clauvel J.-P. Raphael M. Degos L. Sigaux F. Blood. 1995; 86: 1276-1280Crossref PubMed Google Scholar). Epidemiological surveys report that the seroprevalence for HHV8 ranges from 0 to 20% in the general population of the Western world (12Cathomas G. Virchows Arch. 2000; 436: 195-206Crossref PubMed Scopus (42) Google Scholar). Recently, HHV8 seropositivity was observed to be increased in populations exposed to sexually transmitted diseases, such as syphilis or human immunodeficiency virus (HIV), suggesting that HHV8 is also a sexually transmitted pathogen (13Martin J.M. Ganem D.E. Osmaond D.H. Page-Shafer K.A. Macrae D. Kedes D.H. N. Engl. J. Med. 1998; 338: 948-954Crossref PubMed Scopus (595) Google Scholar). As the etiologic agent for KS, HHV8 generally results in latent infection in its natural host cells (14Sarid R. Olsen S.J. Moore P.S. Adv. Virus Res. 1999; 52: 139-142Crossref PubMed Google Scholar). Based on several extensive studies on the association of HIV and the development of KS, it is now understood that HHV8 is required but not necessarily sufficient for the development of KS (15Iscovich J. Biffetta P. Franceschi S. Azizi E. Sarid R. Cancer. 2000; 88: 500-517Crossref PubMed Scopus (223) Google Scholar). In fact, the incidence rate of KS among HIV-1-infected individuals is up to 100,000-fold higher than that among the general population, and 300-fold higher than that for persons with other types of acquired immunosuppression. These findings suggest that immunosuppression likely plays a role as a cofactor with HHV8 in the development of KS; however, they also suggest that HIV-1 infection, independent of its immunosuppressive effects, contributes to HHV8-induced KS (16Beral V. Peteman T.A. Berkelman R.L. Jaffe H.W. Lancet. 1990; 335: 123-127Abstract PubMed Scopus (961) Google Scholar). Accordingly, it has been proposed by several investigators (17Nakamura S. Salahuddin S.Z. Biberfeld P. Ensoli B. Markham P.D. Wong-Staal F. Gallo R.C. Science. 1998; 242: 426-430Crossref Scopus (271) Google Scholar, 18Ensoli B. Barillari G. Gallo R.C. Hematol. Oncol. Clin. North Am. 1991; 5: 281-294Abstract Full Text PDF PubMed Google Scholar, 19Buonaguro L. Buonaguro F.M. Tornesello M.L. Beth-Giraldo E. Del Guadio E. Ensoli B. Giraldo G. Antibiot. Chemother. 1994; 46: 62-72Crossref PubMed Google Scholar) that the role of HIV-1 in KS potentially involves two additional events: HIV-1-induced cytokines production and production of HIV-1 Tat protein. Indeed, cytokines produced by HIV-1-infected cells can induce lytic cycle replication of HHV8, and Tat can activate the vascular epithelial growth factor receptor KDR in endothelial cells (20Morini M. Benelli R. Giunciuglio O. Carlone S. Anrena G. Noonan D.M. Albini A. Biochem. Biophys. Res. Commun. 2000; 273: 267-271Crossref PubMed Scopus (36) Google Scholar). Currently, it cannot be excluded that there may be many yet characterized interactions between HHV8 and HIV-1 that explain the dramatically higher incidence of KS in coinfected individuals. Thus, additional HIV proteins and/or cellular factors induced by HIV-1 could contribute to KS pathogenesis with possibly complex reciprocal effects between HHV8 and HIV-1. Consistent with these thoughts, many herpesviruses such as Epstein-Barr virus (21Romano G. Guan M. Long W.K. Henderson E.E. Virology. 1997; 237: 23-32Crossref PubMed Scopus (13) Google Scholar, 22Guan M. Zhang R.D. Wu B. Henderson E.E. J. Virol. 1996; 70: 7341-7346Crossref PubMed Google Scholar), cytomegalovirus (23Boccuni M.C. Campanini F. Battista M.C. Bergamini G. Dal Monte P. Ripalti A. Landini M.P. AIDS. 1998; 12: 365-372Crossref PubMed Scopus (12) Google Scholar, 24Yurochko A.D. Huong S.M. Huang E.S. J. Hum. Virol. 1999; 2: 81-90PubMed Google Scholar, 25Kim J.-M. Hong U. Jeang K.-T. Kim S. J. Gen. Virol. 2000; 81: 37-46Crossref PubMed Scopus (13) Google Scholar), human herpesvirus 6 (26Geng U. Chandran B. Josephs S.F. Wood C. J. Virol. 1992; 66: 1564-1570Crossref PubMed Google Scholar, 27Asada H. Klaus-Kovtun V. Golding H. Katz S. Blauvelt A. J. Virol. 1999; 73: 4019-4028Crossref PubMed Google Scholar, 28Carrigan D.T. Konx K.K. Tapper M.A. J. Infect. Dis. 1990; 162: 844-851Crossref PubMed Scopus (94) Google Scholar), and human herpesvirus 7 (29Secchiero P. Zella D. Barabitskaja O. Reitz M.S. Capitani S. Gallo R.C. Zunli G. Blood. 1998; 92: 4521-4528Crossref PubMed Google Scholar,30Crowley R.W. Secchiero P. Zella D. Cara A. Gallo R.C. Lusso O. J. Immunol. 1996; 156: 2004-2008PubMed Google Scholar) have been described to influence HIV-1 replication and expression. To decipher mechanistic interplays between HHV8 and HIV-1, several relevant findings need to be considered. Typically, HHV8 is found in B lymphocytes, keratinocytes, epithelial cells, KS tumor cells, and endothelial cells (31Blauvelt A. Adv. Dermatol. 1999; 14: 167-206PubMed Google Scholar). By contrast, the predominant host cells for HIV-1 are CD4+ T lymphocytes, dendritic cells, and mononuclear phagocytes (32Martin J.C. Bandres J.C. J. Acquir. Immune Defic. Syndr. 1999; 22: 413-429Crossref PubMed Google Scholar, 33Weiss R.A. Trop. Med. Int. Health. 2000; 5: A10-A15Crossref PubMed Scopus (8) Google Scholar). Interestingly, Moir and colleagues (34Moir S. Lapointe Malaspina A. Ostrowski M. Cole C.E. Chun T.-W. Adelsberger J. Baseler M. Hwu P. Fauci A.S. J. Virol. 1999; 73: 7972-7980Crossref PubMed Google Scholar) have shown recently that the up-regulation of CD4 and CXCR4 on B lymphocytes mediated by CD40 stimulation leads to increased susceptibility of these B lymphocytes to T-tropic HIV-1 infection. Conversely, dendritic cells and macrophages have been found to be susceptible cells for HHV8 infection (35Froeman K.E. Kash J.J. Eilers D.B. Nickoloff B.J. J. Invest. Dermatol. 1999; 112: 603Google Scholar, 36Moses S.V. Fish K. Ruhl R. Smith P. Chandran B. Nelson J.A. J. Acquir. Immune Defic. Syndr. 1999; 21: A28Crossref Google Scholar). Additionally, HHV8-infected B lymphocytes are further infectable by HIV-1 through a cell-cell-mediated pathway (37Varthakavi V. Browning P.J. Spearman P. J. Virol. 1999; 73: 10329-10338Crossref PubMed Google Scholar). Therefore, it stands to reason that in vivo HHV8 and HIV-1 genomes could coexist in some cells in dually infected individuals. With the goal of elucidating better intracellular interactions between HHV8 and HIV-1, we queried for potential reciprocal effects on gene expression between HHV8 and HIV-1. We found that when the HHV8-positive primary effusion lymphoma cell line BCBL-1 (38Renne R. Zhong W. Herndier B. Kedes D. McGrath M. Ganem D. Nat. Med. 1996; 2: 342-346Crossref PubMed Scopus (914) Google Scholar) was fused to HIV-1-latent ACH2 cells (39Clouse K.A. Powell D. Washington I. Poli G. Strebel K. Farrar W. Barstad P. Kovacs J. Fauci A.S. Folks T.M. J. Immunol. 1989; 142: 431-438PubMed Google Scholar, 40Folks T.M. Clouse K.A. Justement J. Rabson A. Duh E. Kehrl J.H. Fauci A.S. Proc. Natl. Acad. Sci. U. S. A. 1989; 86: 2365-2368Crossref PubMed Scopus (601) Google Scholar), enhanced expression was observed from both HHV8 and HIV-1 genomes. Further analyses indicated that sole expression of the HHV8 KIE2 (41Zhu F.X. Cusano T. Yuan Y. J. Virol. 1999; 73: 5556-5567Crossref PubMed Google Scholar) protein was sufficient to activate the HIV-1 LTR. On the other hand, expression of either HIV Vpr (42Conti L Varano B. Gauzzi M.C. Matarrese P. Federico M. Malorni W. Belardelli F. Gessani S. J. Virol. 2000; 74: 10207-10211Crossref PubMed Scopus (9) Google Scholar) or Tat (43Jeang K.T. Xiao H. Rich E.A. J. Biol. Chem. 1999; 274: 28837-28840Abstract Full Text Full Text PDF PubMed Scopus (377) Google Scholar) was sufficient to modulate HHV8 expression. Our data suggest that reciprocal transcriptional activation between HHV8 and HIV-1 may explain in part the immunosuppression-independent contribution of HIV-1 to HHV8-induced KS. BCBL-1 and ACH2 were obtained from the National Institutes of Health AIDS Research Reagent and Reference Program. Jurkat cells were purchased from the American Type Culture Collection. BCBL-1, ACH2, and Jurkat cells were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum at 37 °C in the presence of 5% CO2. HeLa cells were maintained in Dulbecco's modified Eagle medium supplemented with 10% heat-inactivated fetal bovine serum. For induction of HIV expression in ACH2 cells, 50 ng/ml TPA and 2 μg/ml PHA were added into complete medium (44Pomerantz R. Trono D. Feinberg M.B. Baltimore D. Cell. 1990; 61: 1271-1276Abstract Full Text PDF PubMed Scopus (289) Google Scholar). BCBL-1 cells were treated with 20 ng/ml TPA for 3 days to stimulate HHV8 expression (2Noore P.S. Gao S.J. Dominguez G. Gesarman E. Lungu O. Knowles D.M. Garber R. Pellett P.E. McGeoch E.J. Chang Y. J. Virol. 1996; 70: 549-558Crossref PubMed Google Scholar). HIV latent ACH2 cells were mixed with BCBL-1 in equal number. After washing twice with phosphate-buffered saline, cells were resuspended into 1 ml of 100% (w/v) polyethylene glycol 4000 in RPMI 1640 containing 5% (v/v) dimethyl sulfoxide. The cell/polyethylene glycol suspension was centrifuged at 100 ×g for 2 min, thereafter, 10 ml of RPMI 1640 were added to resuspend the cell pellet. Cells were then centrifuged at 100 ×g for 5 min, supernatant was removed, and cells were finally resuspended into complete medium (46Jeang K.T. Shank P.R. Rabson A.B. Kumar A. J. Virol. 1988; 62: 3874-3878Crossref PubMed Google Scholar). Total RNA was isolated form fused cells with TRIzol reagent (Life Technologies, Inc.) according to the manufacturer's instructions. RNA (50 μg) was hybridized with the 32P-labeled antisense RNA probe (3 × 105cpm). Hybridized reactions were digested with RNase A and RNase T1, and the nuclease-protected RNA probe was analyzed on a 5% denaturing acrylamide gel containing 7 m urea. HIV-1 antisense TAR probe was constructed as described previously (47Quinto I. Mallardo M. Baldasarre F. Scala G. Englund G. Jeang K.-T. J. Biol. Chem. 1999; 274: 17567-17572Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar). Antisense probe to the HHV8 IL-6 sequence (GenBank™ accession no.U93872) from nucleotide 17242 to 17279 corresponding to thevIL-6 coding region was transcribed from the Sp6 promoter in the pGEM IL-6 plasmid, which contains a cloned IL-6 sequence. Antisense actin probe was transcribed using T7 RNA polymerase from vector pTRI-β-actin-human (Ambion, Austin, TX). Protected actin transcript corresponds to a band of 245 bp. The luciferase cDNA under the control of the HIV-LTR (pLTR) was constructed in the pGL2 basic vector. HIV-LTR mutant reporters were as follow: pLSM1 with −111/−94 deletion, pLSM2 with −93/−79 deletion, pLSM3 with −105/−81 deletion, pLSM4 with −75/−58 deletion, and pLSM5 lacking of −57/−40 nucleotides. These luciferase reporter plasmids were from the NIAID AIDS Reagent Repository. The promoter activities of wild-type and mutant HIV LTR were assayed by transiently transfecting BCBL-1 and HeLa cells, which were either mock-treated or treated with TPA for 48 h prior to the transfection. To analyze the transcriptional effects of HHV8 immediate-early genes on HIV LTR, Jurkat cells were transfected with KIE expression vectors and cognate reporter constructs. Amounts of transfected DNA were equalized using pCMV Tag2B. Each transfection also included a cotransfected pCMV β-galactosidase plasmid whose activity was used to normalize for transfection efficiency. 5 × 105 Jurkat cells were transfected using LipofectAMINE 2000 (Life Technologies, Inc.) in a 24-well plate. All transfection reactions were performed in triplicate; values were calculated for standard deviations. Alternatively, BCBL-1 cells (1 × 107) were placed in 0.5 ml of electroporation buffer (RPMI 1640 containing 15% fetal bovine serum, 1 mm sodium pyruvate, 2 mml-glutamine, 1× nonessential amino acids) (48Graves J.D. Gatoh Y. Draves K.E. Ambrose D. Han D.K.M. Wright M. Chernoff J. Clark E.A. Krebs E.G. EMBO J. 1998; 17: 2224-2234Crossref PubMed Scopus (322) Google Scholar) and were mixed with 10 μg of either Vpr or Tat expression vector. Cells were then electroporated at 250 V and 960 microfarads using a Gene Pulser (Bio-Rad Laboratories, Hercules, CA). After pulse application, cells were immediately pelleted by centrifugation and then kept for 20 min at room temperature (49Li L.H. Ross R. Hui S.W. Gene Ther. 1999; 6: 364-372Crossref PubMed Scopus (17) Google Scholar). Transfected cells were cultured in RPMI 1640 supplemented with 20% heated-inactivated fetal bovine serum. The efficiency of transfection was measured by transfecting BCBL-1 with plasmid pEGFP-C (CLONTECH Laboratories, Palo Alto, CA), which contains the enhanced green fluorescence protein gene fused to the CMV immediate-early gene promoter. After 24 h, 40% of the electroporated cells routinely displayed green fluorescence. BCBL-1 cells, which had been chemically induced into lytic cycles, were harvested after exposure to 3 mm sodium butyrate for 4 h. Poly(A)+ RNA was isolated with a QuickPrep Micro mRNA purification kit (Amersham Pharmacia Biotech, Piscataway, NJ) and was reverse-transcribed using a Fast-Run RT-PCR kit (Protech, Taiwan). The cDNA sequences of HHV8 immediate-early genes KIE2,KIE3, and KIE1 type I (41Zhu F.X. Cusano T. Yuan Y. J. Virol. 1999; 73: 5556-5567Crossref PubMed Google Scholar) were based on GenBank™ accession nos. AF091346, AF091347, and AF091348, respectively. The KIE1 gene of HHV8 transcribes three splicing variants ranging from 3.6 to 3.8 kb in length. These species encode three putative open reading frames ORF50, ORFk8.2, and ORFk8α. cDNAs for ORF50, ORFk8.2, and ORFk8α were also cloned separately into expression vectors. The following oligonucleotide primers were used in RT-PCRs: 5′-end of KIE2, 5′-GCGCAAGCTT ATGGCGATGTTTGTG-3′; 3′-end ofKIE2, 5′-GCATCTCGAG TTATCAGTCCAGCCA-3′; 5′-end ofKIE3, 5′-CGCCGATATC ATGCAAATTAGCTTT-3′; 3′-end ofKIE3, 5′-ATATCTCGAG TTATTGAAGCCCAGG-3′; 5′-end ofKIE1–50, 5′-GGGTGATATC ATGGCGCAAGATGAC-3′; 3′-end ofKIE1–50, 5′-GGTACTCGAG TCAGTCTCGGAAGTA-3′; 5′-end ofKIE1–8.2, 5′-GCCGGATATC ATGTTGAAGCTTGGT-3′; 3′-end ofKIE1–8.2, 5′-GGATCTCGAG CTATGTAGGGTTTCT-3′; 5′-end ofKIE1–8α, 5′-CCGCGATATC ATGCCCAGAATGAAG-3′; 3′end ofKIE1–8α, 5′-GCAACTCGAG TCAACATGGTGGGAG. Recognition sites for restriction enzymes are underlined; boldfacenucleotides denote the start (5′-end oligonucleotides) and stop codons (3′-end oligonucleotides). PCR conditions for KIE2and KIE1–8α cDNA amplification were 35 cycles at 94 °C, 1 min; 53 °C, 1 min; and 72 °C, 1 min and that forKIE3, KIE1–50, and KIE1–8.2 were 35 cycles at 94 °C, 1 min; 50 °C, 1 min; and 72 °C, 1.5 min. The PCR-generated fragments of the HHV8 KIE cDNAs were subcloned into pCMV Tag2B (Promega, Madison, WI) to yield flag-tagged pKIE2, pKIE3, pKIE1–50, pKIE1–8.2, and pKIE1–8α. Cells were harvested 72 h post-transfection and were resuspended into lysis buffer (0.5m HEPES, 0.2% Triton X-100, 1 mmMgCl2, 1 mm CaCl2, pH 7.8). After three cycles of rapid freezing and thawing, cell extracts were obtained by centrifugation at 14,000 rpm for 5 min at 4 °C and were analyzed for luciferase activity using a Luciferase assay system (Packard, Meriden, CT). β-Galactosidase assays were performed by incubating cell extracts with an equal volume of β-galactosidase assay buffer (Packard). Readout values of luciferase activity were normalized against corresponding β-galactosidase value for each sample within each experiment. Total RNA (1 μg) was reverse-transcribed using a 1st Strand cDNA synthesis kit for RT-PCR (Roche Molecular Biochemicals, Indianapolis, IN). To ensure that no DNA contaminated the isolated RNA, the RNA samples were treated with DNase I (Stratagene, La Jolla, CA) prior to reverse transcription. The mixtures containing random hexamers for cDNA syntheses were incubated at 25 °C for 10 min and then at 42 °C for 1 h. By heating at 95 °C for 5 min, the avian myeloblastosis virus reverse transcriptase was denatured. As an additional control, each sample was also subjected to reverse transcription in the absence of RT. Two microliters of the cDNA products were then added to 48 μl of PCR reaction mixture, which contained HHV8 major capsid protein primers (forward: 5′-GTACACCTATTTCTTCCCTGTTGG-3′; reverse: 5′-TGCTCATACCTGAGACCGTACC-3′) and internal control 18 S rRNA primers/competitors (Ambion, Austin, TX) at a 2:8 ratio. The 18 S rRNA competitors were modified at their 3′-ends to block extension by DNA polymerase. Amplification was carried out according the following protocol: preheating at 95 °C for 5 min followed by 25 cycles of 95 °C, 58 °C, and 72 °C for 30 s in each segment. The PCR products of major capsid protein (270 bp) and 18 S rRNA (314 bp) were analyzed on a 2.5% agarose gel. To obtain meaningful results, the linear range of relative quantitative RT-PCR was determined by graphing cycles versus products, which were quantitated with an Alpha Innotech Corp. IS-1000 digital imaging system. The amplification was found to be in a linear range of 20 to 29 thermal cycles. To better understand functional interactions between HHV8 and HIV-1, a series of cell fusion experiments was done. We took advantage of the fact that ACH2 and BCBL cells are latently infected with HIV-1 and HHV8, respectively. Both genomes can be activated from latency by treatment of cells with phorbol ester, TPA. By fusing together ACH2 and BCBL cells, heterokaryons can be created, which simultaneously contain both viral genomes. In this manner, potential interactions between the two viruses in the same cell could be assayed. When ACH2 cells were fused with TPA-induced BCBL-1 cells, RNase protection assay showed that HIV-1 TAR-containing RNAs were markedly increased when compared with control samples (Fig.1 A). Because all HIV-1 transcripts contain TAR sequence, this finding suggests that some element associated with the HHV8 genome could activate transcription from the HIV-1 LTR. Indeed, the BCBL-1-mediated transcriptional enhancement was considerably stronger than that achieved by chemically inducing ACH2 cells with TPA and PHA. Thus the observed effect is likely a functional consequence of an HHV8 gene product and not a trivial result of TPA carryover from the induced BCBL-1 cells. Conversely, in a reciprocal experiment, when HHV8 gene expression was analyzed, the level of vIL-6 RNA was increased significantly when BCBL-1 cells were fused with TPA-induced ACH2 cells (Fig.1 B). We next attempted to define the HHV8 responsive element within the HIV-1 LTR. Six scanning mutants that abrogated separately the NF-κB sites, the Sp1 sites, or the TATA element were utilized (Fig. 2 A). Although the basal activities of each of the mutant promoters were different when each was transfected into TPA-stimulated BCBL-1 cells, similar levels of HHV8-associated induction were observed. These results indicate that HHV8-responsiveness involves complex, rather than simple sequence motif(s). Control transfection of the same mutant promoters in HeLa cells (Fig. 2 B) with or without TPA failed to show comparable activation consistent with activation being specific for BCBL-1-associated HHV8 gene product(s). To further clarify how HHV8 activates HIV-1, we sought to identify responsible viral gene product(s). Although current understanding of HHV8 gene functions remains incomplete, we reasoned, based on analogy to other herpesviruses, that immediate-early genes of HHV8 are plausible candidate activators of HIV-1. Hence, we cloned five immediate-early open-reading frames (ORFs) from HHV8 and tested for their effects on the HIV-1 LTR. Our results showed that out of these five ORFs, only KIE2 activated the HIV-1 LTR (Fig.3 A). To check whether activation by KIE2 of HIV-1 LTR correlates with that observed in BCBL-1 cells (Fig. 2) we tested the series of linker-scanning LTR mutants used above. Similar to the activation profiles in Fig. 2, KIE2 activated each linker-scanning mutant comparably (Fig. 3 B). Because the magnitude of activation by KIE2 alone was less than that observed in the ACH2-BCBL-1 fusion experiments (Fig. 1) we considered whether there could be a synergy between this HHV8 protein and the HIV-1 transactivator, Tat. Indeed, when KIE2 and Tat were coexpressed, a significantly synergistic activation was observed for the HIV-1 LTR (Fig. 4). Activation reached a level comparable to that observed in the cell-cell fusions (Fig. 1). The HIV-1 genome encodes two transcriptional transactivators, Tat and Vpr. We reasoned that Tat and/or Vpr might account for HHV8 activation by HIV-1. Using LipofectAMINE, we could achieve only a 10–20% transfection efficiency of BCBL-1 cells. On the other hand, using electroporation we routinely transfected up to 40% of BCBL-1 cells. When BCBL-1 cells were electroporated with expression vectors expressing either Vpr or Tat (Fig. 5) a quantitative RT-PCR assay revealed highly enhanced expression of HHV8 major capsid protein (50Flore O. Gao S.J. AIDS Res. Hum. Retroviruses. 1997; 13: 1229-1233Crossref PubMed Scopus (19) Google Scholar). Thus, functionally, both Vpr and Tat appear to be HIV-1 transcriptional activating counterparts of HHV8 KIE2. HHV8 is a large (∼170 kbp) double-stranded DNA herpesvirus (51Renne B. Lagunoff M. Zhong W. Ganem D. J. Virol. 1996; 70: 8151-8154Crossref PubMed Google Scholar). HIV-1 is a much smaller (∼10 kbp) retrovirus. Despite rather dramatic molecular dissimilarities between the two viral genomes, recent findings have provided compelling evidence that these two viruses interact to promote KS pathogenesis in dually infected individuals. Indeed, it is increasingly clear that, although the HHV8 genome is invariably present in all described cases of KS (6Cathomas G. McGandy C.E. Teracciano L.M. Itin P.H. DeRosan G. Gudat F. J. Clin. Pathol. 1996; 49: 631-633Crossref PubMed Scopus (44) Google Scholar, 8Buonaguro F.M. Tornesello M.L. Beth-Giraldo E. Hatzakis A. Mueller N. Downing R. Biryamwaho B. Sempala D.K. Giraldo G. Int. J. Cancer. 1996; 65: 25-28Crossref PubMed Scopus (118) Google Scholar), most individuals who are singularly infected with HHV8 carry the virus in a latent state and do not present with KS disease. On the other hand, persons infected with both HHV8 and HIV-1 have up to a 100,000-fold increase, compared with infection with HHV8 alone, in risk for developing KS (16Beral V. Peteman T.A. Berkelman R.L. Jaffe H.W. Lancet. 1990; 335: 123-127Abstract PubMed Scopus (961) Google Scholar). Based on this statistic, a reasonable deduction is that HHV8 is necessary but insufficient for producing KS and that HIV-1 is an important cofactor, which promotes HHV8 induced KS. How might HIV-1 contribute to the development of KS? The results from a large multicenter study on HHV8 and HIV-1 infected men established an unmistakable link between HIV-1-associated immunosuppression and HHV8-engendered KS (52Jacobson C.F. Jenkins F.J. Spinger G. Munoz A. Shah K.V. Phair J. Zhang Z.-F. Armenian H. J. Infect. Dis. 2000; 181: 1940-1949Crossref PubMed Scopus (101) Google Scholar). However, in the same study it is interesting that when immunosuppression was excluded, an independent association was revealed between HIV-1 RNA expression and KS progression (52Jacobson C.F. Jenkins F.J. Spinger G. Munoz A. Shah K.V. Phair J. Zhang Z.-F. Armenian H. J. Infect. Dis. 2000; 181: 1940-1949Crossref PubMed Scopus (101) Google Scholar). The latter observation provided the impetus for us to systematically explore potentially more direct interactions between HHV8 and HIV-1. Efforts to identify more direct interactions between HHV8 and HIV-1 have, to date, centered largely on HIV-1-induced cytokines and the secretion of Tat protein from HIV-1-infected cells (53Mercader M. Taddeo B. Punella J.R. Chandran B. Nickoloff B.J. Foreman K.E. Am. J. Pathol. 2000; 156: 1961-1971Abstract Full Text Full Text PDF PubMed Scopus (105) Google Scholar, 54Harrington W. Sieczkowski L. Sosa C. Chan-a-Sue S. Cai J.P. Cabrao L. Wood C. Lancet. 1997; 349: 774-775Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar). Intracellular interactions between the two viruses have been generally discounted, because a prevailing view has been that the two viruses infect different cell types. However, several points argue that such an assumption might not necessarily be warranted. First, it remains unclear as to what are the range of HHV8 susceptible cellsin vivo. Second, recent ex vivo infection studies clearly support that both HHV8 and HIV-1 can efficiently infect cells of the monocyte/macrophage lineage (35Froeman K.E. Kash J.J. Eilers D.B. Nickoloff B.J. J. Invest. Dermatol. 1999; 112: 603Google Scholar, 36Moses S.V. Fish K. Ruhl R. Smith P. Chandran B. Nelson J.A. J. Acquir. Immune Defic. Syndr. 1999; 21: A28Crossref Google Scholar). Finally, Spearman and colleagues (37Varthakavi V. Browning P.J. Spearman P. J. Virol. 1999; 73: 10329-10338Crossref PubMed Google Scholar) have intriguingly demonstrated that HHV8-genome containing B lymphocytes, in fact, can be infected by HHV-1 via a cell-cell pathway and that such infected B lymphocytes could support productive HIV-1 replication. Here we have tried to define which virally encoded component of HIV-1 and HHV8 might reciprocally influence each other's expression inside cells. Our cell fusion results (Fig. 1) indicate that when both genomes exist in the same cellular environment there is a bilateral transcriptional effect between the two viruses. Among the many ORFs that are encoded by HHV8, we found that the KIE2 protein was sufficient for singularly inducing transcription from the HIV-1 LTR (Fig. 3). On the other hand, two HIV-1-encoded factors, Tat and Vpr, were capable of individually activating HHV8 transcription (Fig. 5). Although Tat has previously been invoked to affect HHV8 expression (55Ensoli G. Gendelman R. Markham P. Fiorelli V. Colombini S. Raffeld M. Cafaro S. Chang H.K. Brady J.N. Gallo R.C. Nature. 1994; 371: 674-680Crossref PubMed Scopus (537) Google Scholar, 56Kelly G.D. Ensoli B. Gunthel C.J. Offermann M.K. AIDS. 1998; 12: 1753-1761Crossref PubMed Scopus (29) Google Scholar), the finding here that Vpr provides a similar activity adds further complexity to the interplay between HIV-1 and HHV8. The concept of reciprocal interaction between HHV8 and HIV-1 potentially offers an explanation for the rapid development of KS in HHV8-infected individuals whom are subsequently infected with HIV-1. Thus, in this dually infected subpopulation, the risk for KS development/progression escalates quickly, with a 60% increase for each year of HIV-1 infection (52Jacobson C.F. Jenkins F.J. Spinger G. Munoz A. Shah K.V. Phair J. Zhang Z.-F. Armenian H. J. Infect. Dis. 2000; 181: 1940-1949Crossref PubMed Scopus (101) Google Scholar). If, as suggested here, HIV-1 infection might transcriptionally activate HHV8 genome from latency, and, if such activation of HHV8 leads to further amplification of HIV-1 transcription, then one could imagine how such a feedback-cycle might accelerate disease manifestation. Indeed consistent with this scenario, an interruption of this cycle through treating HIV-1 with reverse transcriptase (RT) or protease inhibitors has been shown to efficaciously induce the regression of KS (45Biggar R.J. Rabkin C.S. Hematol. Oncol. Clin. North. Am. 1996; 10: 997-1010Abstract Full Text Full Text PDF PubMed Scopus (146) Google Scholar). Future investigation toward understanding how to further intervene against the molecular interplay between HHV8 and HIV-1 should usefully advance the treatment of KS. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health: BCBL-1 from Drs. Michael McGrath and Don Ganem and ACH2 cells from Dr. Thomas Folks. human herpesvirus 8 type-1 Kaposi's sarcoma immediate-early 12-O-tetradecanoylphorbol-13-acetate phytohemagglutinin ilterleukin-6 base pair(s) long terminal repeat cytomegalovirus reverse transcriptase polymerase chain reaction kilobase(s) open reading frame kilobase pair(s) RNase protection assay" @default.
• W2144365452 created "2016-06-24" @default.
• W2144365452 creator A5013011418 @default.
• W2144365452 creator A5033037210 @default.
• W2144365452 creator A5047908565 @default.
• W2144365452 creator A5049507002 @default.
• W2144365452 creator A5072656839 @default.
• W2144365452 creator A5073277815 @default.
• W2144365452 creator A5066065120 @default.
• W2144365452 date "2001-04-01" @default.
• W2144365452 modified "2023-10-06" @default.
• W2144365452 title "Reciprocal Regulatory Interaction between Human Herpesvirus 8 and Human Immunodeficiency Virus Type 1" @default.
• W2144365452 cites W1532938692 @default.
• W2144365452 cites W1558279218 @default.
• W2144365452 cites W1583418025 @default.
• W2144365452 cites W1825524617 @default.
• W2144365452 cites W1895715639 @default.
• W2144365452 cites W1961668980 @default.
• W2144365452 cites W1971592398 @default.
• W2144365452 cites W1972008542 @default.
• W2144365452 cites W1997605512 @default.
• W2144365452 cites W1999175037 @default.
• W2144365452 cites W2011574439 @default.
• W2144365452 cites W2020700449 @default.
• W2144365452 cites W2020908945 @default.
• W2144365452 cites W2026414247 @default.
• W2144365452 cites W2027592304 @default.
• W2144365452 cites W2028318125 @default.
• W2144365452 cites W2032438721 @default.
• W2144365452 cites W2032853143 @default.
• W2144365452 cites W2035375271 @default.
• W2144365452 cites W2051188246 @default.
• W2144365452 cites W2062862354 @default.
• W2144365452 cites W2063979760 @default.
• W2144365452 cites W2069600591 @default.
• W2144365452 cites W2079626135 @default.
• W2144365452 cites W2082939502 @default.
• W2144365452 cites W2088950084 @default.
• W2144365452 cites W2089242226 @default.
• W2144365452 cites W2100656561 @default.
• W2144365452 cites W2109335505 @default.
• W2144365452 cites W2110863828 @default.
• W2144365452 cites W2127579025 @default.
• W2144365452 cites W2129623946 @default.
• W2144365452 cites W2132014894 @default.
• W2144365452 cites W2144286914 @default.
• W2144365452 cites W2145419121 @default.
• W2144365452 cites W2146327084 @default.
• W2144365452 cites W2151007255 @default.
• W2144365452 cites W2157166895 @default.
• W2144365452 cites W2159163386 @default.
• W2144365452 cites W2160508776 @default.
• W2144365452 cites W2165667820 @default.
• W2144365452 cites W2168799984 @default.
• W2144365452 cites W2207266486 @default.
• W2144365452 cites W2220908601 @default.
• W2144365452 cites W2312580646 @default.
• W2144365452 cites W2319910375 @default.
• W2144365452 cites W2322698038 @default.
• W2144365452 cites W2331165960 @default.
• W2144365452 cites W2334410844 @default.
• W2144365452 cites W2336241188 @default.
• W2144365452 cites W2337331768 @default.
• W2144365452 cites W2409697147 @default.
• W2144365452 cites W2410723119 @default.
• W2144365452 doi "https://doi.org/10.1074/jbc.m011314200" @default.
• W2144365452 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11154704" @default.
• W2144365452 hasPublicationYear "2001" @default.
• W2144365452 type Work @default.
• W2144365452 sameAs 2144365452 @default.
• W2144365452 citedByCount "79" @default.
• W2144365452 countsByYear W21443654522012 @default.
• W2144365452 countsByYear W21443654522013 @default.
• W2144365452 countsByYear W21443654522014 @default.
• W2144365452 countsByYear W21443654522015 @default.
• W2144365452 countsByYear W21443654522016 @default.
• W2144365452 countsByYear W21443654522017 @default.
• W2144365452 countsByYear W21443654522018 @default.
• W2144365452 countsByYear W21443654522021 @default.
• W2144365452 countsByYear W21443654522022 @default.
• W2144365452 crossrefType "journal-article" @default.
• W2144365452 hasAuthorship W2144365452A5013011418 @default.
• W2144365452 hasAuthorship W2144365452A5033037210 @default.
• W2144365452 hasAuthorship W2144365452A5047908565 @default.
• W2144365452 hasAuthorship W2144365452A5049507002 @default.
• W2144365452 hasAuthorship W2144365452A5066065120 @default.
• W2144365452 hasAuthorship W2144365452A5072656839 @default.
• W2144365452 hasAuthorship W2144365452A5073277815 @default.
• W2144365452 hasBestOaLocation W21443654521 @default.
• W2144365452 hasConcept C159047783 @default.
• W2144365452 hasConcept C2522874641 @default.
• W2144365452 hasConcept C3013748606 @default.
• W2144365452 hasConcept C3018958071 @default.
• W2144365452 hasConcept C86803240 @default.
• W2144365452 hasConceptScore W2144365452C159047783 @default.
• W2144365452 hasConceptScore W2144365452C2522874641 @default.
• W2144365452 hasConceptScore W2144365452C3013748606 @default.
• W2144365452 hasConceptScore W2144365452C3018958071 @default.

• next